• Explore /
  • Poster
  • / Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database.

Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database.

Abstract Poster

Authors

Edoardo Francini

Edoardo Francini

Misericordia Hospital, Grosseto, Italy

Edoardo Francini , Francesco Montagnani , Pier Vitale Nuzzo , Miguel Gonzalez-Velez , Nimira S. Alimohamed , Antonio Cigliola , Irene Moreno , Jaime Rubio , Francesca Crivelli , Grace Shaw , Roberto Petrioli , Carmelo Bengala , Guido Francini , Jesus Garcia Foncillas Sr., Christopher Sweeney , Celestia S. Higano , Alan Haruo Bryce , Lauren Christine Harshman , Richard Lee-Ying , Daniel Yick Chin Heng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 30)

Abstract #

30

Poster Bd #

A18

Abstract Disclosures

Similar Posters

First Author: Li Zhang

First Author: Karim Fizazi

Poster

2021 ASCO Annual Meeting

Bone modifying agents in veterans with castration-resistant prostate cancer.

Bone modifying agents in veterans with castration-resistant prostate cancer.

First Author: Jordan Bauman

First Author: Alison Stopeck